Results 131 to 140 of about 4,747,249 (340)
Oligonucleotide-Based Therapeutics for STAT3 Targeting in Cancer-Drug Carriers Matter. [PDF]
Cancers (Basel), 2023 Molenda S +4 more
europepmc +1 more source
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Molecular Oncology, EarlyView.Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
Recent progress in nanotechnology-based drug carriers for resveratrol delivery. [PDF]
Drug Deliv, 2023 Li C, Wang Z, Lei H, Zhang D.
europepmc +1 more source
Carboxy derivatives of isoflavones as affinity carriers for cytotoxic drug targeting in adrenocortical H295R carcinoma cells [PDF]
, 2003 Dalia Sömjen +6 more
openalex +1 more source
Molecular Oncology, EarlyView.Proteomic and phosphoproteomic analyses were performed on lung adenocarcinoma (LUAD) tumors with EGFR, KRAS, or EML4–ALK alterations and wild‐type cases. Distinct protein expression and phosphorylation patterns were identified, especially in EGFR‐mutated tumors. Key altered pathways included vesicle transport and RNA splicing.
Fanni Bugyi +12 more
wiley +1 more source
Genipin‐crosslinked gelatin microspheres as a drug carrier for intramuscular administration: In vitro and in vivo studies [PDF]
, 2003 Huang‐Chien Liang +3 more
openalex +1 more source
Molecular Oncology, EarlyView.Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh +5 more
wiley +1 more source